NICE again rejects Takeda's Hodgkin's lymphoma drug in draft guidance

15 December 2016

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Japanese drugmaker Takeda’s (TYO: 5402) Adcetris (brentuximab vedotin) to treat some patients with Hodgkin’s lymphoma on the UK's National Health Service (NHS).

Although the guidance from the cost-effectiveness watchdog does not constitute a final verdict, and will be open to public consultation, the initial decision will be a blow to the Japanese company, though the treatment remains available through the UK’s Cancer Drugs Fund for two out of the three indications the NICE is appraising.

A preliminary recommendation not to recommend brentuximab vedotin for routine use was published in NICE draft guidance in August 2016, after which Takeda expressed its dissapointment at the cost watchdog's negative stance on what it sees as a game changer in the treatment of relapsed or refractory Hodgkin's lymphoma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK